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Abstract Regulated preproinsulin gene expression in non-
pancreatic tissues during development has been demonstrated in
rodents, Xenopus and chicken. Little is known, however, about
the synthesis and processing of the primary protein product,
proinsulin, in comparison with these events in pancreas. Using
specific antisera and immunocytochemistry, immunoblot and
HPLC criteria, we characterize the differential processing of
proinsulin in developing neuroretina, liver and pancreas. The
chick embryo pancreas expresses the convertase PC2, and
largely processes proinsulin to insulin. In contrast, little or no
mature PC2 is present in embryonic liver and neuroretina and the
(pro)insulin immunoactivity identified is predominantly proinsu-
lin.
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1. Introduction
Two decades ago, a report by Havrankova et al. [1] initi-
ated the long controversy of whether insulin is produced in
the mammalian brain. Although the issue is not yet fully
resolved for postnatal rodents, an insulin cDNA from adult
rabbit brain has been isolated [2]. Many more reports re£ect
the expression of preproinsulin mRNA during development in
tissues outside the pancreas in multiple species [3^10]. The
ancestral rat insulin II gene has been unequivocally shown
to be expressed and developmentally regulated in liver [3],
yolk sac and brain [4,5]. In both mouse [6] and Xenopus [7]
embryos, the insulin II gene is also expressed in the head
region, prior to pancreas development. The chick embryo is
an ideal model to study the expression of its single insulin
gene in prepancreatic, avascular stages, as well as in the liver
and the neuroretina, an avascular part of the central nervous
system. Sensitive RT-PCR [8] and in situ hybridization [9]
have demonstrated the wide distribution of preproinsulin
mRNA during gastrulation and neurulation. The low levels
of mRNA are translated into a biologically active secreted
protein that attenuated apoptosis in the embryo in vivo and
in culture [9,11]. In the chick embryonic liver, expression of
preproinsulin mRNA was found to be di¡erentially regulated
compared to the pancreas. The main transcript in day 18 of
development (E18) was similar in size in both tissues (V600
base pairs) although it was lower in abundance in liver [10].
No information exists on the translation of this liver tran-
script. During neurogenesis, the expression of preproinsulin
mRNA in the neuroretina has been shown by RT-PCR [12]
and in situ hybridization (Serna, J. et al., manuscript submit-
ted). In addition, a (pro)insulin-related molecule could be im-
munoprecipitated from the culture medium of E5 neuroretina
explants and the insulin immunoactivity found in vivo in the
vitreous humor had the mobility of proinsulin in HPLC [13].
Others have also found insulin-related immunoactivity in
chick embryo retinal extracts [14], but the identity of the pro-
tein produced, whether proinsulin or insulin, was not charac-
terized.
In the pancreas, insulin is typically synthesized as a higher
molecular size precursor, proinsulin, which undergoes limited
proteolytic processing in the secretory granule of the L-cell to
produce mature insulin and C-peptide [15]. This conversion is
catalyzed by the action of two endopeptidases of the subtili-
sin/Kex2 family, the protein convertases PC2 and PC3. Both
PC2 and PC3 are also synthesized as precursors that are proc-
essed to mature forms [16]. PC2 is initially synthesized as a
75-kDa precursor, which yields the active 64/66-kDa protein.
Other members of this endopeptidase family include furin,
highly expressed in the liver during development [17] but
not capable of processing native proinsulin [18]. It is concep-
tually important to determine whether preproinsulin mRNA
in non-pancreatic tissues yields as a ¢nal product proinsulin
or insulin. The former is a poorly active metabolic analog of
insulin [19] but has signi¢cant activity as a growth, di¡eren-
tiation [13] and survival [20] signal in neurogenesis. In this
study, we have investigated the products originated by pre-
proinsulin mRNA translation in the chick embryo neuroretina
and liver, compared to the pancreas. In addition, the expres-
sion of the proinsulin-processing enzyme PC2 is analyzed
throughout ontogeny in these three tissues.
2. Materials and methods
2.1. Chick embryos and tissue explant cultures
Fertilized White Leghorn eggs (Granja Rodr|Łguez-Serrano, Sala-
manca, Spain) were incubated at 38.2‡C and 60^90% relative humid-
ity. At the designated day of development, the organs were dissected
from the embryo, rinsed in cold phosphate bu¡er and used for RNA
or protein extraction. Alternatively, pancreas, liver and neuroretina
explants of embryonic day 15 (E15) were cultured at 37‡C under 5%
CO2 for 4 h, prior to protein extraction, as previously described [8,13].
2.2. Antibodies
Insulin antibodies were bovine insulin antiserum (Sigma Chemical
Co., St. Louis, MO, USA) and porcine insulin antiserum (Bio-Teck,
Winooski, VT, USA), raised in guinea pig. Both recognize chicken
insulin and, less e⁄ciently, proinsulin, but not the IGFs, according to
analysis by dot-blot. Rabbit anti-C-peptide antiserum (Rb40) was
raised in our laboratory using a synthetic chicken proinsulin peptide
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with the amino acid sequence Val39-Glu58 [21]. The multiple antigen
peptide method was used for synthesis (Universitaºt Ulm, Germany).
This antibody is speci¢c for proinsulin and C-peptide; thus, it recog-
nizes neither insulin nor the IGFs. PC2 antiserum (‘Thumpa’, [16])
was kindly provided by Dr. C.J. Rhodes (University of Texas, Dallas,
TX, USA). IgGs were partially puri¢ed for immunocytochemistry by
A⁄-Gel Blue chromatography (Bio-Rad).
2.3. RT-PCR and Southern blotting
Extraction of total RNA from embryonic pancreas, liver and limb,
and RT-PCR for preproinsulin expression analysis were performed as
previously described [8]. The sequences of the chicken-speci¢c oligo-
nucleotides used for the RT-PCR were 5P-atggctctctggatccgatcactg-3P
(upstream) and 5P-gctagttgcagtagttctccagtt-3P (downstream), and for
the DNA hybridization 5P-acgctctccacacaccaggtagag-3P.
2.4. Protein extraction and HPLC
Pancreas, liver and neuroretina at the indicated embryonic age were
homogenized with a ground glass homogenizer in 0.1^0.2 ml of 1 mM
NaHCO3 (pH 7.6) containing 0.2 mM phenylmethylsulfonyl £uoride,
5 Wg/ml pepstatin A, 50 Wg/ml leupeptin, 10 WM E-64 and 10 WM
tosyl-L-lysine chloromethyl ketone (all from Sigma). The homogenate
was then incubated for 30 min on ice, centrifuged at 4‡C for 5 min at
10000Ug, and the supernatant recovered for the PC2 ontogeny stud-
ies. Otherwise, proteins of 4-h cultured E15 pancreas, liver and neuro-
retina were acid ethanol extracted in 0.2 N HCl/75% ethanol (10 ml/g
wet tissue weight) with an Ultra Turrax homogenizer as previously
described [11]. Extracts were incubated at room temperature for 1 h in
0.1% (v/v) TFA and then partially puri¢ed in a C18 Sep-Pak cartridge
(ODS, Waters Associates, Milford, MA, USA), as described elsewhere
[22]. Eluates were dried by evaporation in a vacuum concentrator.
Dried samples were reconstituted in 0.1% TFA and fractionated by
HPLC (LKB system) on a C18 reverse-phase column (Vydac, Hespe-
ria, CA, USA). Elution was at 1.0 ml/min with a 25^65% Bu¡er B
gradient for 40 min (Bu¡er A = 0.1% (v/v) TFA; Bu¡er B = 80% (v/v)
acetonitrile in 0.1% TFA). Fractions were evaporated to dryness and
used for either radioimmunoassay [11] or dot-blot analysis to deter-
mine (pro)insulin immunoactivity. Alternatively, cultured pancreas
extracts were incubated at room temperature for 1 h in 4% (v/v) acetic
acid, loaded onto a C18 Sep-Pak cartridge previously equilibrated in
4% acetic acid, proteins eluted with methanol and dried.
2.5. Protein gel electrophoresis and immunoblotting
Pancreas, liver and neuroretina homogenized as described above
were subjected to conventional SDS-10% polyacrylamide gel electro-
phoresis [23] for the PC2 ontogeny studies. For (pro)insulin analysis,
E15 pancreas and whole retina were homogenized with an Ultra Tur-
rax homogenizer and proteins extracted in acid ethanol (0.2 N HCl/
75% ethanol, 10 ml/g wet tissue weight) as previously described [11].
The extracts were ¢ltered in a Centricon-50 device (Amicon, Beverly,
MA, USA) following the manufacturer’s instructions. The ¢ltrate was
then concentrated with a Centricon-3 device (Amicon) and electro-
phoresed in a Tris-tricine SDS-14% Prosieve polyacrylamide (FMC,
Rockland, ME, USA) non-reducing gel. Proteins were then trans-
ferred onto a nitrocellulose membrane (0.2 Wm, Bio-Rad) using a
semi-dry Trans-Blot unit (Bio-Rad). Membranes were subjected to
immunoblot analysis for PC2 (‘Thumpa’ antiserum, 1:2000), proinsu-
lin (Rb40 antiserum, 1:5000) or insulin/proinsulin (insulin antiserum
from Bio-Teck, 1:2000), using the appropriate secondary antibody
coupled to peroxidase. Proteins were ¢nally detected by chemilumi-
nescence (ECL, Amersham), as described [24].
For the dot-blot of extracts, dried HPLC fractions were reconsti-
tuted in 100 Wl of phosphate bu¡er containing 10 Wg of insulin-free
bovine serum albumin and blotted onto a nitrocellulose membrane
using a vacuum dot-blot apparatus. Insulin/proinsulin immunoactivity
was then developed with an insulin antibody (Bio-Teck) as described
above. For the dot-blot of the standard peptides, puri¢ed chicken
insulin (Litron Lab Ltd., Rochester, NY, USA), our recombinant
chicken proinsulin and chicken IGF-I and chicken IGF-II (both
from GroPep, Adelaide, Australia) were spotted directly onto nitro-
cellulose and overlaid with the insulin antibody and the C-peptide
antibody sequentially.
2.6. Immunocytochemistry
Sixteen micrometer cryosections from E15 eyes and pancreas with
duodenum were prepared and immunostained as previously described
[24] with either a guinea pig anti-insulin IgG (10 Wg/ml) or a rabbit
anti-C-peptide IgG (10 Wg/ml) for 16 h at 4‡C. As secondary anti-
bodies, biotinylated goat anti-guinea pig IgG or goat anti-rabbit IgG
(1:200, Amersham), and Cy2-streptavidin (1:200, Amersham) were
used for 1 h, successively. Immuno£uorescence was visualized by con-
focal microscopy (MRC 1024, Bio-Rad). Guinea pig and rabbit IgGs
were used as negative controls.
3. Results
3.1. Preproinsulin gene expression in developing pancreas and
liver
A highly sensitive and semi-quantitative RT-PCR analysis
followed by Southern blot hybridization demonstrated the
expression of preproinsulin mRNA in the chick embryo liver
(Fig. 1), from E8 to E20 (hatching occurs at E21), extending
our previous studies with Northern analysis [10]. The expres-
sion observed in liver at E8 and E10 was low; it increased
markedly at E13 and E15, and later decreased until E20. On
the contrary, the expression of the preproinsulin mRNA in
the pancreas was much higher at every stage analyzed (con-
sidering the number of PCR cycles used) and showed little
temporal regulation (Fig. 1). Preproinsulin gene expression
in neuroretina has been previously reported to show an early
and a late wave [12].
3.2. Ontogeny of the proinsulin-processing convertase PC2
To establish the possible extrapancreatic proinsulin process-
ing, we searched for the proinsulin-processing enzyme PC2 in
liver, neuroretina and pancreas of the chick embryo. In the
developing pancreas, two speci¢c PC2 immunoactive molecu-
lar forms of apparent molecular weight 75 kDa and 62/63
kDa were detected by immunoblot analysis (Fig. 2). The
75-kDa putative precursor molecular form was present in
low abundance at all stages. Meanwhile, the 62/63-kDa puta-
tive mature form [16] was predominant and developmentally
regulated, showing a progressive increase from E6 to E15. In
the liver, the 75-kDa molecular form was observed, decreasing
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Fig. 1. Expression of the preproinsulin gene in embryonic pancreas
and liver. Total RNA (1.23 Wg) from tissues of the indicated age
(day) were subjected to RT-PCR (20 cycles for pancreas and 30
cycles for liver) and Southern blot analysis. Autoradiograms show
the ampli¢ed DNA fragment (325 base pairs). N, negative control
without RNA template. Control hybridization of the blots with an
IGF-I-speci¢c oligonucleotide detected no signal. Limb RNAs of
the same age embryos were positive for IGF-I expression but nega-
tive for preproinsulin expression (data not shown). For comparable
data on neuroretina see [12].
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in abundance from E6 to E15, meanwhile the 62/63-kDa form
was barely visible only in E6. In neuroretina, these two pro-
tein forms were absent and, although a 70-kDa band is
weakly detected from E9 to E15, we cannot con¢rm that it
is an alternative form of PC2.
3.3. Proinsulin immunoactivity predominates in embryonic liver
and neuroretina and insulin prevails in the pancreas
After having demonstrated preproinsulin gene expression in
developing liver and neuroretina as well as in the pancreas,
and the near undetectable mature PC2 in both non-pancreatic
tissues, we characterized the preproinsulin gene translated
product at E15 by several methods.
Immunocytochemistry with two di¡erent antibodies al-
lowed us to distinguish between insulin and proinsulin. The
¢rst is a commercial insulin polyclonal antiserum that recog-
nizes better insulin, but also proinsulin, and the second is a C-
peptide antiserum speci¢c for chicken proinsulin, hence it does
not recognize fully processed insulin (Fig. 5A). In the pan-
creas, both antibodies stained similar types of granular cells
(Fig. 3B^D), some of which were in small clusters (arrow-
heads in Fig. 3B, and arrow in Fig. 3C) and, thus, identi¢ed
as L-cells of not fully formed islets of Langerhans. Surpris-
ingly, in the neuroretina, these two antibodies had di¡erent
staining preferences. The anti-C-peptide IgG stained clusters
of cells of the ganglion cell layer (arrowheads, Fig. 3E), in a
non-granular, uniform manner, whereas the anti-insulin IgG
only recognized isolated granular cells in the outer neural
layers (Fig. 3F, G) and outside the pigmented epithelium
(Fig. 3G). Pancreas sections treated with guinea pig non-im-
mune IgG showed no speci¢c staining (results not shown).
To further characterize the presence of either proinsulin or
insulin in the chick embryo neuroretina, liver and pancreas,
we performed a HPLC fractionation of both proteins prior to
their immunodetection. A blank injection was run before sam-
ple injections in order to discard any previous (pro)insulin
contamination of the column, and the pancreas extract was
chromatographed after those of liver and neuroretina. Chick-
en insulin and human proinsulin were chromatographed last
as standards, and detected by absorbance at 214 nm. Immu-
noactivity in the chromatographic fractions semi-quanti¢ed by
dot-blot with an insulin antibody (Bio-Teck) that preferen-
tially recognizes insulin, showed a major peak of immunoac-
tivity in the pancreas (Fig. 4A). This peak eluted in the posi-
tion of mature insulin and had a shoulder in the position of
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Fig. 3. Immunocytochemical distribution of insulin and proinsulin in E15 pancreas and retina. Pancreas/duodenum (B^D) and eye (E^G) cryo-
sections were stained for immuno£uorescence with an anti-C-peptide IgG (B, E) or an anti-insulin IgG (C, D, F, G), as described in Section 2.
Phase-contrast images of pancreas (A) and retina (E, insert) sections are also shown. Arrowheads in B indicate clusters of immunostained cells.
Arrow in C marks a group of at least two insulin-containing cells, which is shown in D at a higher magni¢cation. Note that the duodenum is
negative. Arrowheads in E indicate ganglion cells more intensively positive for proinsulin. Arrowhead and arrows in G point at three single
(pro)insulin-containing cells within the retina (arrowhead) and outside the pigmented epithelium (arrows) as observed under phase contrast (not
shown). Bar in G represents 80 Wm for C, 40 Wm for A, B, E, 20 Wm for G, 10 Wm for D and E, insert and 6.3 Wm for F. p, pancreas; d, duo-
denum; gc, ganglion cell; pe, pigmented epithelium. The photographs are confocal microscopy images.
Fig. 2. Ontogeny of the proinsulin-processing enzyme PC2 in em-
bryonic liver, pancreas and neuroretina. Fifty micrograms of total
protein extracts of the indicated embryonic day were subjected to
immunoblot analysis for PC2. The migration of molecular size
standards of the indicated kDa is shown on the right. Arrowheads
indicate the mobility of known speci¢c PC2 molecular forms.
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proinsulin. In both liver and neuroretina, however, only a
small peak of immunoactivity corresponding to the elution
position of standard proinsulin was observed (Fig. 4A). The
HPLC blank run showed no immunoactivity. In a parallel
HPLC fractionation of a larger liver extract, the fractions
were quanti¢ed by insulin radioimmunoassay and the pres-
ence was con¢rmed of immunoactivity with the mobility of
proinsulin (Fig. 4B). The E15 liver concentration of proinsulin
was 3.4 ng/g wet tissue weight, probably a several-fold under-
estimation, since the standard used in the radioimmunoassay
was chicken insulin, better recognized by the antibody. This
corresponds to at least 1 ng per liver, whereas a speci¢c IGF-I
radioimmunoassay for this peptide measured only 0.38 ng per
E15 liver. In addition, we con¢rmed the developmental regu-
lation of proinsulin expression, since the E13 liver extract
contained much less immunoactivity, 0.2 ng/g wet tissue
weight.
Finally, we further demonstrated the synthesis of proinsulin
in the E15 retina by immunoblot. We had previously demon-
strated by metabolic labeling and immunoprecipitation, the
synthesis and rapid secretion of a (pro)insulin-related immu-
noactive protein in the cultured E5 neuroretina [13]. We now
show that E15 retina also contains a protein with the electro-
phoretic mobility of proinsulin (Fig. 5B). This protein was
detected by immunoblotting with both the insulin antibody
and the C-peptide antibody, as would be expected for intact
proinsulin. In contrast, in the pancreas extract, the insulin
antibody identi¢ed a major band with the electrophoretic mo-
bility of insulin and only after a long exposure a higher mo-
lecular weight band, putative proinsulin. Consistent with the
speci¢city of the antibodies (Fig. 5A), the latter was better
recognized by the C-peptide antibody (Fig. 5B).
4. Discussion
This study demonstrates that the insulin-related immunoac-
tivity present in two non-pancreatic tissues of the chick em-
bryo, neuroretina and liver, corresponds predominantly to
unprocessed proinsulin, in contrast to the pancreas, in which
insulin predominates. These ¢ndings strongly support the lo-
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Fig. 5. Immunoblot analysis of insulin and proinsulin in E15 pan-
creas and retina. A: Speci¢city of the antibodies. Recombinant
chicken proinsulin (cPro), IGF-I (cIGF-I) and IGF-II (cIGF-II) and
puri¢ed chicken insulin (cIns) (100 ng of each) were immunoblotted
¢rst with the anti-C-peptide antibody (Rb40, KC-pep) and, after
stripping of the blot, with the anti-insulin antibody (Bio-Teck,
KIns). B: Pancreas (equivalent to 2.3 pancreas=0.07 g of wet tissue
weight) and retina (pool of 12=0.36 g of wet tissue weight, contain-
ing traces of pigmented retina) extracts were subjected to Tris-tricine
SDS-polyacrylamide gel electrophoresis under non-reducing condi-
tions and then immunoblotted, using sequentially the anti-C-peptide
antibody and the anti-insulin antibody as in panel A. Puri¢ed chick-
en insulin (500 ng) was electrophoresed as standard (open arrow-
head). The mobility of proinsulin (solid arrowhead) in this type of
gel coincided with a multimeric rather than monomeric form of
standard proinsulin. The exposures were adjusted for best observa-
tion of the relevant band, therefore, the proinsulin band of the pan-
creas extract in the overlay with anti-insulin antibody was visible
only in a longer exposure.
Fig. 4. HPLC analysis of insulin and proinsulin in E15 pancreas,
liver and neuroretina. A: Pancreas (pool of 17 = 0.10 g of wet tissue
weight), liver (pool of 2 = 0.40 g of wet tissue weight) and neuroreti-
na (pool of 5 = 0.18 g of wet tissue weight) acid alcohol extracts
were subjected to HPLC. Fractions (1 min) were analyzed by dot-
blot with an insulin antibody (Bio-Teck) and ECL. B: Acidic liver
extracts (pool of 19 = 5.7 g of wet tissue weight) were subjected to
C18 reverse-phase HPLC and the collected 1.0-min fractions were
tested in an insulin radioimmunoassay, that recognizes insulin and
proinsulin, but not IGFs. Arrows indicate the elution position of
chicken insulin (I) and human proinsulin (PI) standards.
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cal synthesis of proinsulin outside the pancreas. The presence
of preproinsulin gene expression regulated during develop-
ment in non-pancreatic tissues [3^14], although low in concen-
tration, was already suggestive of local production of the fac-
tor. Studies at the protein level are scarce, however, because
of the di⁄culty in characterizing a very low abundance small
protein in embryonic tissues. Further, tissues such as liver,
yolk sac or young embryos lack typical endocrine secretory
granules, in which proteins can be concentrated about 200-
fold [25]. In contrast, these tissues secrete proteins through the
constitutive pathway that, if used by proinsulin, would result
in continuous, rapid secretion [4,9,13]. The corresponding low
cytoplasmic protein levels are thus much more di⁄cult to
detect [6,9]. We had previously postulated that the prepancre-
atic and extrapancreatic translation product of the preproin-
sulin gene could remain as proinsulin, and that it had a role in
developmental events such as proliferation, di¡erentiation and
survival [9,13,20,26]. Recently, we have con¢rmed by immu-
nocytochemistry that proinsulin is present in E1^E2 embryos
(Serna, J., unpublished observation) where it modulates apop-
tosis [9]. Indirect evidence showed that the neuroretina pro-
duced proinsulin, since during proliferative stages (E6^E8),
the immunoactivity accumulated in the vitreous humor, in
contact with the neuroretina and ciliary processes, had the
HPLC mobility of proinsulin [13]. In the present analysis,
we chose to study the neuroretina at a later stage of develop-
ment (E15), during neuronal maturation, to better compare it
with a presumably more mature pancreas and with liver at its
preproinsulin gene expression peak. For this purpose, we gen-
erated a speci¢c chicken C-peptide antibody to discriminate
immunologically the intact proinsulin from insulin, which
lacks that region. The clusters of immunostained cells found
in the pancreas were not yet completely arranged as typical
islets, a feature similar to that found in other developing em-
bryos [27]. Since they were similarly immunostained by an
insulin antibody and the C-peptide antibody, these insulin-
rich embryonic L-cells may contain some proinsulin stored
in granules as well. In contrast, in the E15 neuroretina, the
immunocytochemistry showed proinsulin-speci¢c staining in
patches of ganglion cells, reminiscent of the expression pattern
of IGF-I mRNA [28] and compatible with the broad pre-
proinsulin mRNA distribution detected by in situ hybridiza-
tion (Serna, J. et al., manuscript submitted). In addition, a few
isolated cells of stronger, insulin-speci¢c granular staining ap-
peared either in the outer layers of the retina or outside the
pigmented epithelium, in the choroid. These cells are morpho-
logically similar to macrophages/microglia, a type of granular
cell reported to invade the chick embryo retina [29] and to
contain NGF [30], among other growth factors, important in
the balance of cell death/survival during neurogenesis. The
de¢nitive characterization of these cells, their production of
preproinsulin mRNA and their capacity to process proinsulin
into mature insulin will require future studies.
As for the liver, the insulin-related immunoactivity was also
characterized as proinsulin by immunological and HPLC cri-
teria. We did not perform immunocytochemistry, but prelimi-
nary in situ hybridization had shown di¡use preproinsulin
mRNA in the embryonic liver [10]. The ¢nding of proinsulin
in both neuroretina and liver, in contrast with the predomi-
nantly processed insulin of the pancreas, concurs with the
di¡erential expression of PC2 in these tissues. While the pan-
creatic PC2 increased with embryonic age between E6 and
E15, no similar 62/63-kDa band was detectable in the neuro-
retina and was only barely visible in the liver. This result is
similar to that found in mammalian embryos, in which PC2
and PC3 have been detected in the developing pancreas, but
not in the liver or the retina [17]. Both PC2 and PC3 function
naturally in the regulated secretory pathway and require the
granule environment to process proinsulin e⁄ciently. In fact,
no mature insulin has been detected in L-cell compartments
other than the secretory granule [31]. Indeed, slow cleavage
has even been described in transformed L-cells that lack an-
other endoprotease, PC1/PC3 [32]. In these cells the ratio of
proinsulin to insulin is higher than in normal L-cells and
proinsulin uses the constitutive secretion pathway. Similarly,
in a rat pancreatic tumor model, the absence of PC1 and PC2
coexisted with lack of conversion of proinsulin to insulin [33].
Other endopeptidases such as furin process precursors in the
constitutive pathway. We cannot rule out that the ubiquitous
furin, the PC2 precursor or other endopeptidase(s) may be
able to convert chicken proinsulin into insulin more slowly,
but it appears unlikely that the process is very e⁄cient in
neuroretina and liver during mid-development, in accordance
with results shown here.
We can only speculate about the autocrine-paracrine role of
this proinsulin in two tissues as di¡erent as neuroretina and
liver at E15. It is possible that it has a cell survival function
similar to that observed at earlier stages of embryogenesis
[9,20] or it may have additional roles, for example, in neuro-
nal maturation. The concentration of proinsulin found in the
vitreous humor at E8 (V55 ng/ml) [13] is high enough to bind
and activate the retina atypical insulin receptors [20]. It is also
interesting that, in mid-embryogenesis, the production of
IGF-I in the liver is negligible (see Section 3 and also [34]).
As proposed in the fetal rat [3], liver (pro)insulin may also act
in the chick embryo in an endocrine mode to accomplish both
metabolic and growth e¡ects. The situation of high levels of
circulating proinsulin may be more physiological in lower
vertebrates, such as ¢sh, in which both insulin and proinsulin
are considered growth factors [35]. In the chick, proinsulin
appears also to deserve its own place as a developmental
multifunctional tissue factor.
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